Barclays
INO icon

Barclays’s Inovio Pharmaceuticals INO Stock Holding History

Barclays’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84K Buy
3,487
+2,981
+589% +$3.54K ﹤0.01% 4800
2026
Q1 		$880 Sell
506
-216
-30% -$356 ﹤0.01% 4904
2025
Q4 		$1.26K Buy
722
+721
+72,100% +$1.59K ﹤0.01% 5076
2025
Q3 		$2 Sell
1
-81
-99% -$155 ﹤0.01% 5433
2025
Q2 		$167 Sell
82
-36,327
-100% -$69.6K ﹤0.01% 5095
2025
Q1 		$59.3K Sell
36,409
-2,705
-7% -$5.43K ﹤0.01% 4575
2024
Q4 		$71.6K Buy
39,114
+5,111
+15% +$22.6K ﹤0.01% 4665
2024
Q3 		$197K Buy
34,003
+25,116
+283% +$207K ﹤0.01% 4310
2024
Q2 		$71.8K Buy
+8,887
New +$93.5K ﹤0.01% 4062
2023
Q3 		– Sell
-5,393
Closed -$28.9K – 4647
2023
Q2 		$28.9K Sell
5,393
-66,172
-92% -$533K ﹤0.01% 4051
2023
Q1 		$704K Sell
71,565
-41,236
-37% -$703K ﹤0.01% 3002
2022
Q4 		$2.11M Buy
112,801
+16,428
+17% +$372K ﹤0.01% 2229
2022
Q3 		$2M Buy
96,373
+95,454
+10,387% +$2.44M ﹤0.01% 1749
2022
Q2 		$19K Sell
919
-2,030
-69% -$57.2K ﹤0.01% 4423
2022
Q1 		$126K Sell
2,949
-17,965
-86% -$809K ﹤0.01% 3685
2021
Q4 		$1.25M Buy
20,914
+13,806
+194% +$1.11M ﹤0.01% 2681
2021
Q3 		$611K Buy
7,108
+3,686
+108% +$370K ﹤0.01% 3079
2021
Q2 		$380K Sell
3,422
-9,580
-74% -$920K ﹤0.01% 3232
2021
Q1 		$1.45M Sell
13,002
-3,921
-23% -$516K ﹤0.01% 2536
2020
Q4 		$1.8M Sell
16,923
-3,834
-18% -$510K ﹤0.01% 2311
2020
Q3 		$2.89M Sell
20,757
-941
-4% -$196K ﹤0.01% 1797
2020
Q2 		$7.02M Buy
21,698
+5,612
+35% +$901K 0.01% 1151
2020
Q1 		$1.44M Buy
16,086
+8,354
+108% +$515K ﹤0.01% 2591
2019
Q4 		$306K Buy
7,732
+2,915
+61% +$87.7K ﹤0.01% 4707
2019
Q3 		$119K Sell
4,817
-637
-12% -$19.4K ﹤0.01% 5351
2019
Q2 		$192K Buy
5,454
+3,407
+166% +$135K ﹤0.01% 5143
2019
Q1 		$92K Sell
2,047
-3,910
-66% -$197K ﹤0.01% 5422
2018
Q4 		$286K Sell
5,957
-468
-7% -$28.4K ﹤0.01% 4324
2018
Q3 		$429K Buy
6,425
+5,527
+615% +$308K ﹤0.01% 4402
2018
Q2 		$42K Sell
898
-1,313
-59% -$72.4K ﹤0.01% 5740
2018
Q1 		$125K Sell
2,211
-4,378
-66% -$237K ﹤0.01% 5222
2017
Q4 		$326K Buy
6,589
+4,837
+276% +$300K ﹤0.01% 4262
2017
Q3 		$134K Buy
1,752
+19
+1% +$1.41K ﹤0.01% 4724
2017
Q2 		$163K Buy
1,733
+1,504
+657% +$129K ﹤0.01% 4534
2017
Q1 		$18K Sell
229
-271
-54% -$21.6K ﹤0.01% 5845
2016
Q4 		$42K Sell
500
-924
-65% -$83.5K ﹤0.01% 5274
2016
Q3 		$160K Buy
1,424
+1,409
+9,393% +$156K ﹤0.01% 4150
2016
Q2 		$2K Sell
15
-412
-96% -$50.1K ﹤0.01% 5955
2016
Q1 		$41K Buy
427
+346
+427% +$26.7K ﹤0.01% 4885
2015
Q4 		$5K Sell
81
-4,854
-98% -$386K ﹤0.01% 5568
2015
Q3 		$298K Buy
4,935
+4,814
+3,979% +$419K ﹤0.01% 3805
2015
Q2 		$12K Sell
121
-203
-63% -$21.7K ﹤0.01% 6000
2015
Q1 		$31K Sell
324
-142
-30% -$13.8K ﹤0.01% 5601
2014
Q4 		$50K Sell
466
-133
-22% -$16.3K ﹤0.01% 5714
2014
Q3 		$65K Buy
599
+481
+408% +$59.9K ﹤0.01% 5657
2014
Q2 		$14K Sell
118
-106
-47% -$12.5K ﹤0.01% 6663
2014
Q1 		$33K Sell
224
-306
-58% -$43.9K ﹤0.01% 6303
2013
Q4 		$51K Buy
+530
New +$53K ﹤0.01% 6169

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's INO Position: Q2 2026 in Review

Barclays increased its Inovio Pharmaceuticals (INO) stake by 589% in Q2 2026, buying an estimated $3.54K and bringing the position to 3,487 shares worth $3.84K. The position accounts for ﹤0.01% of the portfolio, ranked #4800.

Barclays first reported a position in INO in Q4 2013 and has held it in 48 quarters since. The position peaked at $7.02M in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Barclays held 3,487 shares of Inovio Pharmaceuticals worth $3.84K as of Q2 2026.
  • Barclays bought 2,981 Inovio Pharmaceuticals shares in Q2 2026, an estimated $3.54K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4800 holding.
  • Barclays first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 48 quarters since.
  • Barclays's Inovio Pharmaceuticals position peaked at $7.02M in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.